| Mirdametinib to Reduce the Size of Large/Giant Congenital Melanocytic Nevi in Children, Adolescents and Young Adults | Mirdametinib | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 2026-10-23 |
| A Single-Arm,Multicenter Phase, Phase II Clinical Trial of Adebrelimab Combined With Trametinib in the Treatment of Refractory Recurrent Langerhans Cell Histiocytosis in Children and Adolescents | Trametinib | Phase 1 / Phase 2 | Enrolling by invitation | Second Affiliated Hospital of Wenzhou Medical University | 2026-10-22 |
| Observational Study of the Real-world Effectiveness and Safety of Selumetinib Treating Adult Patients With Neurofibromatosis Type 1 (NF1) Who Have Symptomatic, Inoperable Plexiform Neurofibroma (PN) | Selumetinib | — | Recruiting | AstraZeneca | 2026-10-22 |
| Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid Cancer | Trametinib | Phase 2 | Not yet recruiting | Washington University School of Medicine | 2026-10-21 |
| A Study of QL1706 Combined With OH2 Injection in Perioperative Treatment of Stage III Resectable Acral Melanoma | Trametinib | Phase 4 | Not yet recruiting | Peking University Cancer Hospital & Institute | 2026-10-02 |
| A Study of Mirdametinib in Infants and Toddlers With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas | Mirdametinib | Phase 1 | Not yet recruiting | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | 2026-09-30 |
| A Study to Assess the Effects of Probenecid on the Pharmacokinetics of Mirdametinib and Its Metabolites in Healthy Participants | Mirdametinib | Phase 1 | Recruiting | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2026-09-25 |
| Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic Adenocarcinoma | Avutometinib | Phase 1 / Phase 2 | Not yet recruiting | University of Virginia | 2026-09-17 |
| Clinical Trial of a MEK Inhibitor for RASopathy-Associated Severe Infantile Hypertrophic Cardiomyopathy: Baby MERIT | Trametinib | Phase 3 | Not yet recruiting | Carelon Research | 2026-09-14 |
| Molecularly Tailored Therapy in Advanced Pancreatic Cancer | Trametinib | Phase 2 | Not yet recruiting | Herlev Hospital | 2026-09-03 |
| Safety and Feasibility of First-line Avutometinib and Defactinib in Patients With Newly Diagnosed High-grade Gliomas | Avutometinib | Early phase 1 | Not yet recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2026-08-21 |
| A Real-World Study of Second-line Therapies Among Radioiodine-refractory Differentiated Thyroid Cancer (RAI-R DTC) Patients | Trametinib | — | Not yet recruiting | Novartis Pharmaceuticals | 2026-08-18 |
| A Study of Clinical Practice and Real-world Care of Patients Treated With mTOR, PI3K, and MEK Inhibitors for Extracranial Vascular Anomalies | Trametinib | — | Not yet recruiting | Novartis Pharmaceuticals | 2026-08-17 |
| Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) | Avutometinib | Phase 2 | Not yet recruiting | Verastem, Inc. | 2026-08-05 |
| Combination of Avutometinib and Defactinib for Treatment of Relapsed, Refractory, Metastatic, or Unresectable Malignant Peripheral Nerve Sheath Tumor | Avutometinib | Phase 2 | Not yet recruiting | Girish Dhall, MD | 2026-08-04 |
| Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2) | Selumetinib | Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 2026-07-20 |
| Selumetinib for NF2-Related Schwannomatosis | Selumetinib | Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 2026-07-16 |
| Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma | Selumetinib | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 2026-06-02 |
| 24VA021; VATCH Trametinib for Ras/MAPK Pathway VAs | Trametinib | Phase 2 | Recruiting | Children's Hospital of Philadelphia | 2026-04-24 |
| A Study of Mirdametinib in People With Central Nervous System Tumors | Mirdametinib | Phase 1 / Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 2026-04-20 |
| Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma | Mirdametinib | Phase 2 | Not yet recruiting | University of Alabama at Birmingham | 2026-04-13 |
| Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma | Cobimetinib | Phase 2 | Recruiting | Hanmi Pharmaceutical Company Limited | 2026-03-04 |
| Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas | Cobimetinib | — | Active, not recruiting | Blokhin's Russian Cancer Research Center | 2026-03-04 |
| Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer | Avutometinib | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 2026-01-06 |
| Mirdametinib in Patients With Advanced NF1-mutant Melanoma | Mirdametinib | Phase 2 | Recruiting | Kevin Kim, MD | 2025-11-19 |
| Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma | Avutometinib | Phase 2 | Recruiting | Washington University School of Medicine | 2025-08-17 |
| Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia | Mirdametinib | Phase 2 | Recruiting | National Cancer Institute (NCI) | 2025-07-14 |
| UK ENcorafenib and BInimetinib Real-world Study in Melanoma | Binimetinib | — | Active, not recruiting | Pierre Fabre Ltd | 2025-06-15 |
| Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib | Mirdametinib | Phase 1 | Recruiting | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | 2025-05-30 |
| Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases | Binimetinib | Phase 2 | Recruiting | Grupo Español Multidisciplinar de Melanoma | 2025-03-20 |
| Using Tumor Models to Determine Treatments | Cobimetinib | Phase 2 | Recruiting | University Health Network, Toronto | 2025-02-06 |
| Real-life Pharmacological Monitoring of Encorafenib-Binimetinib in the Treatment of Metastatic Melanoma | Binimetinib | — | Recruiting | Assistance Publique - Hôpitaux de Paris | 2025-01-14 |
| Low-dose Selumetinib for the Treatment of Plexiform Neurofibromas in Chinese Children | Selumetinib | Phase 2 | Not yet recruiting | West China Hospital | 2025-01-08 |
| Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST | Selumetinib | Phase 1 / Phase 2 | Recruiting | AeRang Kim | 2024-12-16 |
| A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients | Avutometinib | Phase 2 | Active, not recruiting | Verastem, Inc. | 2024-11-12 |
| 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours | Avutometinib | Phase 1 / Phase 2 | Recruiting | Institute of Cancer Research, United Kingdom | 2024-10-08 |
| Clinical Study on the Treatment of Type I Neurofibromatosis With Smeitinib Hydrosulfate Capsule | Selumetinib | Phase 2 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2024-10-01 |
| The Clinical Study of the Treatment of Patients With Type I Neurofibromatosis With Smetinib Hydrosulfate Capsule | Selumetinib | Phase 2 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2024-10-01 |
| Circulating Tumour DNA Guided Adaptive BRAF and MEK Inhibitor Therapy | Binimetinib | Phase 2 | Not yet recruiting | The Christie NHS Foundation Trust | 2024-06-24 |
| Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation | Cobimetinib | Phase 2 | Recruiting | City of Hope Medical Center | 2024-06-04 |
| Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer | Binimetinib | Phase 2 | Recruiting | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | 2024-01-17 |
| Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer | Binimetinib | Phase 2 | Recruiting | National Cancer Center, Japan | 2023-12-06 |
| DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. | Cobimetinib | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 2023-03-14 |
| DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol | Cobimetinib | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 2023-02-10 |
| Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers | Cobimetinib | Phase 1 | Active, not recruiting | National Cancer Institute (NCI) | 2023-01-20 |
| Personalized Medicine for Advanced Biliary Cancer Patients | Binimetinib | Phase 3 | Recruiting | UNICANCER | 2022-11-14 |
| Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) | Binimetinib | Phase 2 | Active, not recruiting | National Cancer Institute (NCI) | 2022-10-03 |
| The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs | Cobimetinib | Phase 2 | Recruiting | Helsinki University Central Hospital | 2021-12-16 |